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Herpes simplex virus 1 (HSV-1) infects a significant number of people 
worldwide and is the number one cause of infectious blindness in western 
industrialized countries.  HSV-1 causes a lifelong latent infection that can be 
reactivated by various stressors.  HSV-1 E3 ubiquitin ligase phosphoprotein, 
infected cell protein 0 (ICP0), is a potent global transcriptional activator of genes 
and is required for productive viral replication and reactivation from latency.  
While the phosphorylation state of ICP0 is important for regulating many 
activities of ICP0, there is only a minimal amount known about which specific 
cellular kinases are important for modulating these activities.  Studies with HSV-
1 have been done with Roscovitine (Rosco), which inhibits CDK1, CDK2, CDK3, 
CDK5, CDK7, and CDK9 have shown that Rosco impairs HSV-1 replication, 
reactivation, the transactivation activity of ICP0, and it alters the 
posttranslational modification state of ICP0.  It is not known which of these 
specific kinases are required for regulating these activities. 
This thesis summarizes my studies to identify specific cellular kinases 
that are required for the transactivation activity of ICP0 and regulate its other 
key functions to promote efficient viral replication and reactivation from latency.  
To begin to elucidate which specific cellular kinases are important for the 
transactivation activity of ICP0, we developed a high throughput cell-based 
assay using HSV-1 GFP reporter viruses with small interfering (siRNA) in a 96-
well plate format.  siRNA library used in screens was against ~700 known and 
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putative cellular kinases, from which I identified several (~21) potential regulators 
of ICP0’s ability to stimulate viral gene expression. 
From the list of kinase candidates, we focused our studies on cyclin-
dependent kinases (CDKs) 1, 2, 4 and 6, which are associated with the cell cycle 
and did not appear to have an inhibitory effect on ICP0 protein expression in 
siRNA-transfected cells.  We decided to use specific CDK inhibitors to examine 
the role activities of specific CDKs play in modulating ICP0 function.  Our data 
shows that inhibiting CDK1 impaired HSV-1 replication in an ICP0-dependent 
manner, while the replication of wild-type (WT) HSV-1 and an ICP0-null mutant 
was diminished when the CDK2 inhibitor was tested.  We then examined the 
effect of these CDK inhibitors on viral protein expression in WT HSV-1 infected 
cells.  While the CDK1 inhibitor reduced levels of UL42, an early protein; the 
CDK2 inhibitor had a much greater effect by decreasing or inhibiting UL42, 
ICP8, US11, and VP5 expression.  None of the CDK inhibitors appeared to have 
an effect on ICP0 localization or ND10 disruption.  Finally, using a quiescent 
infection model, we demonstrated that inhibitors of CDKs 1 and 2 repressed 
ICP0-induced reactivation of viral gene expression.  These results strongly 
suggest that CDK1 regulates an aspect of ICP0’s transactivation activity, which 
in turn enhances HSV-1 lytic infection and reactivation.  While CDK2 also 
appears to regulate (at least in part) ICP0’s ability to stimulate gene expression 
during lytic replication and reactivation, it also aids HSV-1 productive infection 
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Chapter 1: Introduction 
1.1 Herpes simplex virus type 1 (HSV-1) 
Human herpesvirus 1 or herpes simplex virus type 1 (HSV-1) is known to 
infect approximately 70-80% of the population worldwide [1].  The most 
common sign of infection in humans is a cold sore that can form around the 
mouth or lips, although the infection in some individuals is asymptomatic [1].  
HSV-1 is also capable of infecting eyes and is the number one cause of 
infectious blindness in western industrialized countries [1].  HSV-1 can also be a 
cause of genital herpes and can cause encephalitis in immuncompromised 
individuals. 
HSV-1 is an enveloped virion and contains a proteinaceous layer 
underneath the envelope known as the tegument, which surrounds an 
icosahedral nucleocapsid.  The envelope of the virus, which is derived from the 
host cell membrane, contains glycoproteins that transverse the envelope and 
aid the virus in attaching and entering into the cell.  The viral genome within the 
capsid is a large, linear double-stranded DNA genome that is approximately 152 
kilobases [1].  HSV-1 infects only humans and is a member of alphaherpesvirus 
subfamily [1].  HSV-1 can infect a variety of cell types including neurons of the 
trigeminal ganglia that innervate cells at the peripheral oral-facial region. 
1.1.1 HSV-1 life cycle 
HSV-1 infects cells by attaching to cellular receptors of the cells using 
glycoproteins expressed on the envelope of the virus or through membrane 
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fusion with the cell [2].  Once inside the cell the nucleocapsid is transported to 
the nuclear pore, and the viral genome is transferred into the nucleus and 
circularizes.  HSV-1 expresses three different classes of genes/proteins in a 
temporal fashion: immediate early (IE), early (E), and late (L) proteins [3].  The 
transcription of IE genes is stimulated by the tegument protein, viral protein 16 
(VP16), and the cellular proteins Oct-1 and HCF.  IE proteins assist HSV in 
evading the antiviral defenses of the host cells and transcriptionally activating E 
and L genes.  E proteins are important for viral DNA replication, which is 
required to efficiently stimulate L genes.  L genes are the last HSV transcripts to 
be transcribed and translated into proteins that are either components of virus 
assembly, viral structure, or viral egress from the cell.   
 The virus has two different life cycles: lytic and latent cycle.  The lytic 
cycle is briefly described in the previous paragraph.  After initial infection and 
replication of the virus, HSV-1 can then infect the neurons that innervate the 
oral-facial region known as the trigeminal ganglia, where the virus can become 
latent.  When HSV-1 is latent, only the latency-associated transcripts (LATs) are 
actively expressed and lytic viral proteins are not translated.  Various stressors, 
such as UV, hormone changes, fever, etc, can then reactivate the virus.  This 
reactivation initiates active virus replication in the neurons, which eventually 
leads to viral replication at the primary site of infection allowing the virus to 
spread from person to person [1]. 
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1.2 Immediate-early proteins 
HSV-1 encodes five immediate-early (IE) proteins.  The IE proteins include 
infected cell protein 0 (ICP0), infected cell protein 4 (ICP4), infected cell protein 
(ICP22), infected cell protein 27 (ICP27), and infected cell protein 47 (ICP47).  
Both ICP4 and ICP27 are required for viral replication in cell culture [4-8].  ICP0 
is an E3 ubiquitin ligase that inactivates cellular antiviral defenses and 
transactivates viral genes (more about ICP0 will be discussed in subsection 1.3).  
ICP4 is the major transcriptional activator of HSV-1 genes and is an essential 
viral gene required for virus replication.  ICP22 is required for efficient viral 
replication and the formation of virus-induced chaperone-enriched (VICE) 
domains in cells; however, ICP22 is not essential for viral replication except in 
certain cell lines.  The other essential IE protein, ICP27, is important for 
posttranscriptional processing and export of viral transcripts [9-11].  ICP47 aids 
the virus in evading the immune response by inhibiting transporter associated 
with antigen processing (TAP), so that viral antigens will not be presented on 
MHC Class I molecules of infected cells, which is required for the activation of 
cytotoxic T cells [12, 13].  Of the five IE proteins, four (ICP0, ICP4, ICP22, and 
ICP27) have been shown to be phosphorylated [14-16]. 
1.3 Infected Cell Protein 0 (ICP0) 
ICP0 is a 110 kDa phosphorylated viral protein that is imperative for both 
efficient viral replication [17-20] and reactivation from latency [21, 22].  ICP0 has 
many different functions, many of which are related to its E3 ubiquitin ligase 
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activity.  The E3 ubiquitin ligase activity is affiliated with the really interesting 
new gene (RING)-finger domain located within the N-terminus of ICP0 (Fig. 1.1) 
[23, 24].  ICP0 E3 ubiquitin ligase activity causes the degradation of many 
cellular proteins and disruption of nuclear domain 10 (ND10) structures [25, 26].  
ICP0 is also a global gene transactivator that can transactivate all three HSV-1 
gene classes [27-32].   The RING-finger domain is required for the ability of ICP0 
to transactivate reporter gene expression [33], thus showing that the RING-
finger domain is necessary for the transactivation activity of ICP0.  The RING 
finger domain in ICP0 and its E3 ubiquitin ligase activity are also responsible for 
inactivating the cellular DNA damage response [34-36] and diminishing 
chromatinization and other repressive modifiers of the HSV-1 genome [37], 
aiding virus replication.  ICP0 was also shown to inhibit interferon-stimulated 
genes during HSV infection [38].  Evading and/or impairing the interferon 
response allows HSV-1 from being inhibited by this innate response, which then 
allows the virus to continue to spread from cell to cell or even from person to 
person.   
1.4 ICP0 and phosphorylation 
ICP0 is a phosphoprotein and has been shown to be phosphorylated at 
11 sites that are located in 3 regions of the protein (Fig. 1.1) [39], which we 
referred to as the Phos regions.  An additional phosphorylation site was 
identified at site 67 (threonine) of ICP0, and this site appears to be important for 
the binding and degradation of the DNA damage protein, RNF8 [40].  The 3 
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aforementioned phosphorylated regions of ICP0 were mutated from serines (S) 
or threonines (T) to alanines  (A) to prevent their phosphorylation, and the 
resulting mutations were called Phos 1, Phos 2, and Phos 3 [39].  Phos 1, with 
four mutated sites, has reduced transactivating activity, impaired ND10 
disruption, as well as reduced viral replication in cell culture and in vivo (mice) 
[39, 41, 42].  Phos 2, which has 3 sites mutated, is impaired for ND10 disruption 
and showed reduced viral replication [39, 41, 42].   Phos 3, which has 4 
phosphorylation sites mutated, did not have any significant phenotypes that 
diverged from WT HSV-1 in tissue culture or in mice [39, 41, 42].   
Since the sites in region 1 seemed to have the most physiological 
relevance for the protein/virus, further studies were done to determine which 
specific sites were important for regulating specific activities of ICP0 [43].  To 
this end, individual sites were mutated to alanine (A) within region 1, in addition 
to one double mutant amino acid positions 224 and 226 [43].  It was found that 
S224A and double mutant S224A/T226A were more stable than WT ICP0, 
implying that its E3 ubquitin ligase activity was impaired in these two mutant 
forms of ICP0 [43].  This increase in protein stability with S224A and 
S224A/T226A correlated with reduced viral replication in cell culture and in vivo 
[43].  
1.5 Kinases, phosphorylation, and IE proteins 
Of the five immediate early proteins, four of them (ICP0, ICP4, ICP22, and 
ICP27) are phosphorylated.  Though the virus encodes two viral kinases, UL13 
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and US3, cellular kinases are also important for phosphorylating these proteins.  
UL13 is known to phosphorylate ICP22 [15, 44].  Phosphorylation of ICP4 
appears to be important for cell replication in neurons and also during 
establishing latency in the mouse model [45].  ICP4 appears to be 
phosphorylated by protein kinase A [45, 46].  ICP27 is also a phosphoprotein, 
and ICP27 phos mutant viruses have impaired viral replication and impaired viral 
gene expression in addition to the protein losing the ability to interact with 
certain cellular export factors [14, 47-49].  Both UL13 and cellular kinases are 
shown to be important for the phosphorylation of ICP0, the latter of which will 
be discussed in more detail in the next section.  Though we know that UL13 
phosphorylates ICP0, ICP0 is also phosphorylated in the absence of other viral 
proteins [50], leading us to believe that cellular kinases may be important for 
regulation the phosphorylation state of ICP0, which in turn regulates activities of 
ICP0.       
1.6 CDKs, the cell cycle, and ICP0 
Cyclin-dependent kinases (CDKs) are an integral part of regulating the 
cell cycle, which is important for cell replication or proliferation.  In general, 
CDKs phosphorylate cellular proteins that are important for cell cycle 
progression and transitions.  These kinases are activated by being 
phosphorylated on a specific site when bound by specific cyclin partners.  
Consequently, CDKs are activated by distinct cyclins depending on which 
specific phase of the cell cycle one or more cyclins are expressed; in contrast 
7 
 
CDKs tend to be expressed at fairly constant or steady state levels throughout 
the cell cycle.  Given that many CDKs are active during different times in the cell 
cycle, these kinases have the capability of phosphorylating different targets.  Of 
the CDKs associated with the cell cycle, CDK4 and CDK6 are important for 
progression in the G1 phase [51, 52] and phosphorylate certain cellular proteins 
such as retinoblastoma tumor suppressor protein at the G1 to S phase transition 
[51, 52].  CDK1 controls G2 phase, the G2/M transition, and M phase of the cell 
cycle.   CDK2 is active during the G1/S transition [51, 52] and S [53] phases of 
cellular proliferation.   
Although ICP0 is known to be highly phosphorylated, as previously 
discussed in section 1.4, not much is known about which specific cellular 
kinases influence its phosphorylation state.  Published studies have been 
performed with the CDK inhibitor, Roscovitine (Rosco), which inhibits CDK1, 
CDK2, likely CDK3, CDK5, CDK7, and CDK9.  Rosco impaired the 
transactivation activity of ICP0 [54], an important function of ICP0, establishing a 
connection between ICP0 and CDKs.  In addition to its impaired transactivation 
activity, the posttranslational modification status of ICP0 is altered by Rosco, 
suggesting the Rosco-sensitive CDKs may phosphorylate ICP0 [54].  ND10 
disruption (e.g., dissociation of PML and Sp100) was not, however, affected in 
HSV-1-infected cells treated with Rosco [55].  Rosco also impaired HSV-1 
replication in cell culture and reactivation by explanting latently infected tissue 
[56, 57].  During the course of explant-induced reactivation in HSV-1 infected 
mouse trigeminal ganglia, CDK2 and/or CDK4 expression increased over time 
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[57], potentially linking CDK expression to ICP0, as ICP0 is required for efficient 
reactivation (Halford et al., 2001, Halford and Schaffer, 2001).  Expression of 
ICP0 during viral infection or in the absence of over viral proteins has been 
shown to block cellular proliferation at the G1/S and G2/M transitions [58, 59].  
Interestingly, these transition phases require CDK1, CDK2, CDK4 and CDK6.  
This does put forth the possibility that ICP0 and CDKs regulate one another.  
Another potential relationship between ICP0 and specific CDKs come form 
bioinformatics studies regarding regions of ICP0 phosphorylation; these studies 
indicate that regions I and II of ICP0 phosphorylation contain potential CDK1 
and CDK2 consensus phosphorylation sites [39].  Furthermore, CDK1 has been 
shown to phosphorylate exon 1 of ICP0 in vitro [60], and a purified GST-CDK4 
fusion protein has been shown to interact with ICP0 in pull-down from infected 
cell extracts [61]. 
 Though we know that Rosco (CDK inhibitor) inhibits ICP0 transactivation 
[54], that specific CDKs can phosphorylate and/or interact with ICP0 [60, 61], 
and that phosphorylation regulates activities of ICP0 [39-43, 54, 55], we don’t 
know which specific cellular kinases are responsible for regulating the activities 
of ICP0.  In order to begin to elucidate which specific cellular kinases are 
important for regulating activities of ICP0, we decided to initially develop a high 
throughput cell-based assay with an siRNA library to identify which potential 
cellular kinases are important for the transactivation activity of ICP0 described in 
Chapter 2 [62].   After identifying a number of cellular kinases that appeared to 
be important for ICP0’s transactivation activity, we decided to focus on CDK1, 
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CDK2, CDK4, and CDK6 due to the connection with ICP0 and these specific 
cellular kinases in previously published reports [54, 58-61] and from the results 
in our siRNA screen (Fowler, et. al., in prep).   We took the approach to 
determine which specific CDKs are important for regulating the activities of ICP0 
and HSV-1 by using specific CDK inhibitors.  We determined at that the 
activities of two CDKs are crucial for controlling ICP0 activities and HSV-1 
replication and reactivation, as will be discussed in Chapter 3. 
1.7 Figure and Figure legends 
 
Figure 1.1  HSV-1 ICP0 structure and functional domains. 
This figure has been modified from Davido, et. al., 2005.  Select functional 





Chapter 2: Development of a novel cell-based assay to monitor 
the transactivation activity of the HSV-1 protein ICP0 
 
This chapter was published August of 2015, Volume 120: pages 1-6 in 
Antiviral Research.  Authors are: Angela M Fowler, Heather E Shinogle, and 
David J Davido. 
 
2.1 Introduction 
Herpes simplex virus type 1 (HSV-1) infects 70-80% of the population 
and commonly causes cold sores, although many infections are asymptomatic 
[1]. HSV-1 can also cause ocular infections and is the major cause of infectious 
blindness in western industrialized countries [1].  Initially, HSV-1 infects epithelial 
cells at a primary site, resulting in a lytic infection.  The virus can then infect the 
sensory neurons that innervate the infected epithelial cells, where it establishes 
a life-long latent infection.  Reactivation of latent virus can occur by different 
stresses, which initiates lytic infection in neurons and ultimately epithelial cells at 
the primary site of infection.  This cycle of latent and lytic infections leads to 
recurrent disease.  One viral protein that is important for efficient for viral 
replication and reactivation from latency is the immediate-early (IE) protein, 
infected cell protein 0 (ICP0) [17, 27, 63]. 
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ICP0 is one of the five HSV-1 IE proteins and has RING-finger motif [64, 
65] that allows ICP0 to function as an E3 ubiquitin ligase [66]. E3 ubiquitin 
ligases are components of an E1-E2-E3 biochemical pathway that conjugates 
and polymerizes chains of ubiquitin onto proteins [67]. This activity of ICP0 
directs the degradation of specific cellular proteins [25, 26, 68-71], which in turn 
impairs cellular antiviral defenses.  The E3 ubiquitin ligase activity of ICP0 is also 
linked to the ability of ICP0 to act as a potent global transcriptional activator of 
viral genes [72, 73].  Previous studies have shown that the transactivation 
activity of ICP0 is important for efficient HSV-1 replication and reactivation from 
latency [18, 74, 75].  Although the transactivating activity of ICP0 has been 
studied in the absence of other IE genes in transient transfection assays [33, 39, 
43, 76], it has not been extensively studied independent of other IE proteins in 
the context of a viral infection.  A limited number of cellular factors have been 
linked to ICP0’s transactivation activity [54, 77]; however, the development of a 
cell-based assay to monitor this activity would allow for the systematic 
identification of key cellular factors or activities (e.g., via siRNA knockdown) that 
contribute to this function.   
To begin to elucidate cellular factors that affect ICP0’s transactivating 
activity, we have developed an assay that measures this activity of ICP0 in a 96-
well plate format. The assay was developed using two HSV-1 reporter viruses 
that express only ICP0 of the 5 IE genes (d106) or none of the IE genes (d109).  
Both viruses have a human cytomegalovirus major immediate early promoter 
(HCMV MIEp) driven green fluorescent protein (GFP) in the HSV-1 ICP27 locus 
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[78].  Similar to other published reports [38, 75, 79, 80], we show here that ICP0 
is capable of transactivating the HCMV MIEp; in the case of d106, ICP0 
transactivation activity is quantified by measuring GFP fluorescence levels using 
a Typhoon Imager.  To ultimately adapt this screen to use siRNAs against cell 
targets, we demonstrate that ICP0’s transactivating activity was minimally 
affected when cells were transfected with an siRNA against the cellular house 
keeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH).   Using a 
96-well plate format, we established that d106 (+ICP0) has higher levels of GFP 
than d109 (-ICP0), which increase from 12 to 24 h post infection (hpi).  Lastly, 
we use this assay in an siRNA library screen and identify that an siRNA against 
ubiquitin activating enzyme E1-like (UBEL1) impairs the transactivation activity 
of ICP0, validating the development of our assay. 
2.2 Materials and Methods 
2.2.1  Cell culture and viruses 
HeLa S3 (human cervical carcinoma) cells (kindly provided by Ira Blader) 
were utilized in the assay and grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 10% fetal bovine serum (FBS), 2 mM L-glutamine, 10 U/mL 
penicillin, 10 U/mL streptomycin, and 50 µg/mL gentamycin at a temperature of 
37°C in 5% CO2.    
HSV-1 recombinant viruses, d106 and d109 (Fig 2.1, modified [78], kindly 
provided by Neal DeLuca) were used in our cell-based assay.  Of the 5 IE genes, 
d106 only expresses ICP0 (+ICP0), whereas d109 does not express any IE 
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proteins (-ICP0).  Both viruses express the GFP gene from the human 
cytomegalovirus major IE promoter (HCMV MIEp).  Both d106 and d109 viruses 
were grown on M17 cells, which are a derivative of Vero cells stably transformed 
with the HSV-1 ICP4 and ICP27 genes (kindly provided by David Leib).  
Adenoviral vectors, Ad-crtTA and Ad-T-ICP0, were used to infect M17 and 
transiently express ICP0 to increase titers of d109.  Ad-crtTA and Ad-TICP0 
were grown and titered as previously described [22].  d106 was titered on Vero 
cells and d109 was titered on L7 cells (Vero cells that contain the ICP0 gene) 
[81], and fluorescent forming units were counted 24 hpi.  M17, Vero, and L7 
cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 
5% fetal bovine serum (FBS), 2 mM L-glutamine, 10 U/mL penicillin, 10 U/mL 
streptomycin, and 50 µg/mL gentamycin at a temperature of 37°C in 5% CO2. 
2.2.2  Reverse transfection 
HeLa S3 cells were reverse transfected in BD Falcon black well clear 
bottom optilux 96-well plates (San Jose, California, catalog # 08-772-104).   
Ambion siRNAs (Grand Island, NY) were used at a volume of 10 µL per well and 
final concentration of 10 µM per well.  The ubiquitin pathway siRNA library 
(Ambion, Grand Island, NY, Catalog number #AM80991V3) was used at the 
same volume and concentration.  siRNA was pre-plated in wells of the 96-well 
plate.  0.2 µL of Lipofectamine 2000 per well was mixed with 9.8 µL Opti-MEM 
per well for 10-25 min.  The Lipofectamine 2000/Opti-MEM mix is added to the 
pre-plated siRNA and allowed to incubate for 20 minutes.  After the 20 min 
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incubation, HeLa S3 cells were added to the wells at 8,000 cells per well in 80 
µL per well in penicillin/streptomycin free 10% FBS DMEM.  Transfected and 
mock-transfected wells were washed twice with complete medium 24 h post 
transfection (hpt) and then 100 µL of HeLa S3 cell medium was added to each 
well.  48 hpt, medium was removed from the cells and the well was either 
infected with previously described reporter viruses or harvested for RNA 
isolation. 
2.2.3  Infection 
HeLa S3 cells were infected 48 hpt with d106 or d109 reporter viruses at 
a multiplicity of infection (MOI) of 1.  Viruses were diluted in HeLa S3 medium 
that did not contain phenol red.  Infections were allowed to proceed for 12, 18, 
and 24 hpi.   
2.2.4  Detection and analysis of fluorescent signals 
Plates were scanned using a Typhoon image scanner (General Electric 
Healthcare) at standard settings according the manufacturer’s 
recommendations.  Settings were chosen to scan green fluorescence at an 
excitation of 488, emission of 520, and photomultiplier tube (PMT) of 475 and 
excitation of 633, emission of 670, and photomultiplier tube (PMT) of 475 for the 
deep red.  Scans were done at 12, 18, and 24 hpi.  At the 24 h time point for the 
siRNA screen, cells were stained with deep red mitotracker in FBS-free DMEM 
at a final concentration of 250 nM as per protocol (Invitrogen, Grand Island, NY, 
catalog # M22426) to account for cell density.  The fluorescence intensity of 
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each scanned well was analyzed in ImageJ by using a circle the size of the well 
& measuring the intensity of each well.  Data was copied into Excel (Microsoft) 
software for analysis.  Wells that contained only cells and medium were used as 
background controls, and this value was subtracted from values of infected 
wells.  For the siRNA screen, the GFP intensity was normalized to the 
mitotracker (deep red) intensity.  d106 values were set at 100% and mock 
transfected, GAPDH siRNA transfected d106, d109 values were compared to 
the 100% value.  For the siRNA screen, similar calculations were done, but 
normalized values were used instead of GFP only values.  Lastly, the percent 
average variation for all d106 signals using the data in presented in Fig. 2.5 was 
calculated to be 3% of the mean d106 signal. 
2.2.5  RNA isolation and reverse transcription real time PCR 
Cells were lysed and harvested using Trizol (Invitrogen, Grand Island, NY) 
according to manufacturer’s recommendations.  RNA was isolated using 
phenol-chlorform extraction.  500 ng of RNA was reverse transcribed to make 
cDNA using the iScript BioRad cDNA synthesis kit (BioRad, Hercules, CA, 
catalog # 170-8890) according to manufacturer’s conditions.  Real time PCR 
was done by using SYBR green master mix (Roche) and standard conditions 
were used for the cellular target, GAPDH (5’-CGGATTTGGTCGTATTGGGCGC-
3’ and 5’-TCCCGTTCTCAGCCTTGACGGT-3’), and the normalization control, 
hTBP (5’-TGCACAGGAGCCAAGAGTGAA-3’ and 5’-
CACATCACAGCTCCCCACCA-3’) [82].  Standard curves were obtained for the 
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target and normalization control.  Comparisons were made using the ∆∆2CT 
method, setting the untransfected control at 100%.  
2.3 Results 
2.3.1  ICP0 transactivates the HCMV MIEp-GFP.   
With the long-term goal of identifying cellular factors that play a role in the 
transactivating activity of ICP0, we sought to develop a 96-well plate cell-based 
assay.  We initially wanted to establish if the replication-defective reporter 
viruses, d106 (+ICP0) and d109 (-ICP0) [78], could be used in this format.  
Specifically, we wanted to use fluorescence as an output of ICP0’s 
transactivation activity.  Both d106 and d109 viruses contain an HCMV MIEp-
GFP reporter, and previous studies indicate that ICP0 can transactivate the 
HCMV MIEp  (Fig. 2.1).  We first tested whether the expression of GFP is 
dependent on ICP0 in HeLa cells, a cell type commonly used to study HSV-1 
replication that is highly transfectable for nucleic acids (e.g., siRNA and DNA 
plasmids) [33, 83].  HeLa S3 cells were infected with d106 (+ICP0) or d109 (-
ICP0), and GFP expression was examined by microscopy at 2, 6, 12, and 24 h 
post infection (hpi).  Activation of the HCMV MIEp-GFP was first detected by 6 
hpi for d106 (+ICP0) and steadily increased until 24 hpi (Fig. 2.2).  In contrast, 
activation of HCMV MIEp-GFP in d109 (-ICP0) became apparent by 12 hpi in a 
subset of cells (Fig. 2.2), with increased GFP expression by 24 hpi (Fig. 2.2).  
Although the GFP is induced in d109 (-ICP0)-infected cells, it does not reach the 
level, both in relative fluorescence intensity and cell number, as d106 (+ICP0)-
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infected cells.  This experiment indicated that ICP0 potently induced the HCMV 
MIEp-GFP reporter construct in d106; thus, we established that d106 can be 
used as a reporter virus for monitoring ICP0 transactivating activity.   
2.3.2  siRNA depletion of GAPDH does not appear to affect ICP0’s 
transactivation activity by fluorescence microscopy. 
We next wanted to know if transfecting an siRNA against a cellular 
housekeeping gene would affect the transactivating activity of ICP0.  For this 
experiment, HeLa S3 cells were untransfected, mock transfected, or transfected 
with an siRNA targeted against GAPDH.  Mock-transfected cells were included 
in these experiments to determine if the transfection reagent alone modulated 
ICP0’s transactivating activity.  As indicated in Figure 2.3, we observed no 
notable differences in GFP levels of d106 (+ICP0)- or d109 (-ICP0)-infected cells 
that were untransfected, mock transfected, and GAPDH siRNA-transfected via 
microscopy. 
2.3.3   GAPDH transcript levels are depleted in a 96-well plate format.   
Once we showed that transfection of siRNAs into cells did not appear to 
affect GFP levels of d106 (+ICP0) or d109 (-ICP0)-infected cells as imaged by 
microscopy, we next wanted to confirm that we could deplete the transcript 
levels of a cellular target using an siRNA in a 96-well plate format.  HeLa S3 cells 
were untransfected, mock transfected, or transfected with a siRNA targeting 
GAPDH in triplicate wells.  Forty-eight h post transfection (hpt), RNA from each 
well was isolated, reverse transcribed into cDNA, and analyzed by Real Time 
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PCR.  Transcript levels of GAPDH were significantly reduced to 3.4% of 
untransfected levels in the siRNA-transfected samples and to 75% in mock-
transfected samples compared to untransfected samples, which were given the 
value of 100% (Fig. 2.4).  This experiment shows that we are able to reduce 
mRNA levels of a specific cellular target in a 96-well plate substantially.  
2.3.4  An siRNA against GAPDH has a minimal affect on ICP0’s 
transactivation activity in a 96-well plate.   
After we established that an siRNA against GAPDH depleted its transcript 
levels using a 96-well plate, we adapted this assay using the d106 and d109 
reporter viruses to a 96-well plate format.  HeLa S3 cells were untransfected, 
mock transfected, or transfected with a siRNA against GAPDH.  At 48 hpt, HeLa 
S3 cells were mock infected in triplicate or infected with d106 or d109 at an MOI 
of 1.  The 96-well plate was scanned for fluorescence using a Typhoon Imager 
at 12 hpi, 18 hpi, and 24 hpi.  GFP expression was detected at 12 hpi for d106 
(+ICP0) (Fig. 2.5A), which gradually increased at 18 and 24 hpi (Fig. 2.5A).  For 
each time point, d106 (+ICP0) GFP levels are visibly higher than d109 (-ICP0), 
with d109 GFP intensities were reduced 5-6 fold at 12 hpi, 9.5-12 fold at 18 hpi, 
and 10.4-14 fold at 24 hpi (Fig. 2.5B) relative to d106, whether in the absence or 
presence of the GADPH siRNA.  Lastly, there results confirmed our microscopy 
studies in which an siRNA against GAPDH did not appreciably affect GFP 
intensities for d106- or d109-infected wells compared their respective 
untransfected controls (Fig. 2.5B).  These experiments demonstrate that we can 
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examine the transactivation activity of ICP0 using d106 in a cell-based assay in 
a 96-well plate format.    
2.3.5  An siRNA against UBE1L impairs the transactivation activity of 
ICP0. 
Utilizing our 96-well plate cell-based assay, we screened a small siRNA 
library that targeted components of the ubiquitin pathway.  Wells were reverse-
transfected and infected with d106.  From this screen, an siRNA against UBE1L, 
an E1 enzyme of the ubiquitin-proteasome pathway, impaired the 
transactivation activity of ICP0 5.5-fold at 24 hpi (Fig. 2.6), which began to 
approach d109 (-ICP0) GFP levels (Fig. 2.6). Thus, we demonstrate that this 
assay can be used in an siRNA screen having identified a target in the ubiquitin-
proteasome pathway.  
2.4 Discussion 
In this paper, we have demonstrated, in line with other studies [75, 79, 
80], that ICP0 can potently transactivate the HCMV MIEp (Fig. 2.2).  We also 
found that an siRNA against the housekeeping gene, GAPDH, does not appear 
to affect the transactivation activity of ICP0 as measured by microscopy (Fig. 
2.3) and that GAPDH transcripts could be depleted to significant levels in a 96-
well plate format (Fig. 2.4).  These results indicate that siRNA technology can be 
used in this cell-based assay in a 96-well plate format.  We also established that 
the Typhoon Imager is a quick and valid method to examine ICP0’s 
transactivating activity in a 96-well plate format (Fig. 2.5), and we verified that 
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the assay can be used to screen an siRNA library by identifying an ubiquitin-
proteasome pathway target, UBE1L (Fig. 2.6).  Overall, we have concluded that 
the reporter viruses, d106 and d109, can be utilized in a cell-based assay by 
using a 96-well plate format and Typhoon image scanner. 
While this system is adaptable to siRNA or small molecule inhibitor 
screens, this method also has several advantages over other established 
methods used to examine ICP0’s transactivation activity [33, 43, 54, 76].  
Specifically, ICP0’s transactivation activity can be monitored in the context of a 
viral infection, in the absence of other IE proteins, and at multiple time points in 
one experiment or infection by the assaying of live cells.  In contrast, other 
methods monitor this activity in the context of a viral infection but in the 
presence of other IE proteins [54], which may complicate the interpretation of 
certain studies.  Transient transfection reporter assays have been used to 
examine ICP0’s transactivation activity independent of other IE proteins, but 
these assays are not done in the setting of a viral infection [33, 43, 76].  Finally, 
most viral reporter assays and transient transfection assays can only monitor 
one time point per sample because the cells will either have to be lysed or fixed 
to analyze the sample, in contrast to our system.  Thus, the d106/d109 reporter 
assay is advantageous because it can be used to monitor multiple time points 
for one experiment and monitor ICP0’s transactivation activity in the absence of 
IE proteins while in the context of a viral infection.  Furthermore, the inclusion of 
d109 can also be used in counter-screens to verify that targets or inhibitors are 
specific for ICP0.  
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In summary, we have developed a cell-based assay for ICP0 that can use 
siRNA technology or small molecule inhibitors in a 96-well plate format.  This 
assay can also be modified for use in a high throughput screen with the 
inclusion of viability indicators such as alamarBlue [84].  Notably, this assay will 
likely increase our knowledge related to the regulation of ICP0’s transactivating 
activity, which may eventually lead to potential treatments against HSV-1 and its 
recurrent diseases.  
 
Contribution to this work:  I did all the experimental design, setup, and analyses 
described in this chapter, with the exception for the set up of data analyses. 
2.5 Figures and Figure Legends 
 
Figure 2.1  HSV-1 recombinant viruses, d106 and d109, utilized in our cell-
based assay. 
Of the 5 IE genes, d106 only expresses ICP0 (ICP0+), whereas d109 does 
not express any IE proteins (ICP0-).  Both viruses express the GFP gene from 
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the human cytomegalovirus major IE promoter (HCMV MIEp).  This figure is 
modified from Samaniego, et. al., 1998. 
 
Figure 2.2  ICP0 transactivates the HCMV MIEp-GFP.   
HeLa S3 cells were seeded in a 12-well plate, and mock-infected or infected at 
an MOI of 1 FFU per cell of d106 or d109 per cell.  Cells were examined by 
fluorescence microscopy at 2, 6, 18, and 24 h post infection (hpi), and images 
were captured with a digital camera.  Light microscopy images are located on 





Figure 2.3  siRNA depletion of GAPDH does not affect ICP0’s 
transactivation activity. 
HeLa S3 cells were untransfected, mock transfected or transfected with an 
siRNA directed against GAPDH.  Mock-transfected cells were included in these 
experiments to determine if the transfection reagent alone modulates ICP0’s 
transactivating activity.   All samples were compared to the untransfected 
control.  Forty-eight hpt, HeLa S3 cells were infected with an MOI of 1 with d106 
or d109 for 24 h and viewed by fluorescence microscopy.  Light microscopy 
images are located on the left and fluorescent images are located on the right 




Figure 2.4  GAPDH transcript levels are depleted in a 96-well plate.   
HeLa S3 cells were untransfected, mock transfected, or transfected with a 
siRNA targeting GAPDH in triplicate wells in a 96-well plate.  Twenty-four hpt, 
well were washed as described in materials and methods.  Forty-eight hpt, RNA 
was isolated from each well, reverse transcribed into cDNAs, and analyzed by 
Real Time PCR. Comparisons were made using the ∆∆2CT method.  GAPDH 
transcript levels were compared between mock- and GAPDH-transfected cells 
relative to the untransfected control, which was set at 100%.  Error bars 




Figure 2.5  An siRNA against GAPDH has a minimal effect on ICP0’s 
transactivation activity in a 96-well plate format.   
HeLa S3 cells were untransfected, mock transfected, or transfected with 
an siRNA against GAPDH. At 48 hpt, HeLa S3 cells were mock infected or 
infected with d106 or d109 at an MOI of 1.  (A) The 96-well plate was scanned 
using a Typhoon Imager at 12 hpi, 18 hpi, and 24 hpi.  This experiment was 
repeated in triplicate 2 times.  (B) Comparisons of d106 and d109 samples – 
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untransfected d106 samples were set at 100% for all time points, and mock 
transfected and siRNA-transfected samples were compared to it. Error bars 
represent SEMs. 
 
Figure 2.6  An siRNA against UBE1L impairs the transactivation activity of 
ICP0.   
HeLa S3 cells were seeded in a 96-well plate.  Cells were reverse 
transfected as described in the protocol.  Wells that contained siRNA against 
the ubiquitin ligase pathway were infected with d106 at an MOI of 1, 48 hpt.  
Cells were untransfected or transfected with GAPDH siRNA for controls.  48 hpt, 
control wells were infected d106 or d109 or mock infected.  The 96-well plate 
was scanned using a Typhoon Imager at 24 hpi.  Comparisons were made 
relative to d106-untransfected infection, which was set at 100% (far left bar for 
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each graph).  UBEL1 is ubiquitin-activating enzyme E1-like.  Error bars represent 




Chapter 3  Activities of one or more CDKs play roles in HSV-1 
gene expression and replication and facilitate reactivation from 
a quiescent infection in an ICP0-dependent manner. 
3.1 Introduction 
Herpes simplex virus type 1 (HSV-1) infects 70%-80% of the world 
population [1].  Herpes simplex virus type 1 (HSV-1) typically infects fibroblasts 
and epithelial cells on or around the mouth and lips.  Primary infection caused 
by HSV-1 is typically mild or asymptomatic; however, HSV-1 can also cause 
very severe diseases such as infectious blindness and encephalitis.  The virus 
can exist in two states of infection: lytic and latent.  The lytic infection of HSV-1 
is characterized by a temporal cascade of gene expression including three 
classes of genes: immediate early (IE), early (E), and late (L) [85].  Once HSV-1 
replicates in the initial site of infection, it then infects neurons that innervate the 
primary infection site.  It can establish a latent state in neurons that is 
characterized by limited viral gene expression and a lack of infectious virus [86].  
Various stressors can cause the virus to reactivate, leading to lytic infection in 
neurons and cells at the initial site of infection.  The IE viral protein infected cell 
protein 0 (ICP0) plays an important role in both efficient lytic infection and 
reactivation from latency [17, 18, 63]. 
ICP0 is one of five IE proteins expressed by HSV-1 and is a 
multifunctional phosphorylated protein that has a zinc RING-finger motif that 
controls its E3 ubiquitin ligase activity [66].  ICP0 transactivates all three classes 
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of HSV-1 genes as well as non-HSV-1 genes [27, 30-32, 87].  As an E3 ub 
ligase, it has ability to degrade components of the host’s antiviral nuclear 
domain (ND) 10 [25, 26] and interferes with the chromatinization of viral DNA 
[88-91].  All of these activities of ICP0, including its ability transactivate viral 
genes, are linked to its E3 ub ligase activity [25, 72].  
It has been know for several decades that ICP0 is a phosphorylated 
protein [14], and this post-translational modification appears to regulate many of 
its functions [39-43].  Phosphorylation sites in each of three identified regions 
(termed 1, 2, and 3) were blocked by site-directed mutagenesis, creating the 
mutant forms of ICP0: Phos 1, 2, and 3 [39].  Out of the three Phos mutants 
generated, Phos 1 showed the greatest impairment for transactivation activity 
[39, 41], E3 ub ligase activity [41], increased ICP0 stability [41], and reduced 
replication in cell culture and in mice [41] and reduced reactivation [42].  Within 
this region, the serine at 224 was largely responsible for these phenotypes [43].  
Phos 2 was impaired for replication in the eyes and trigeminal ganglia of mice 
and for reactivation from latency by explanation [42].  Mutation of region 3 
appeared to replicate and reactivate similarly to WT HSV-1. 
Although phosphorylation has been linked to the regulation of ICP0 
activities, little is known about the specific kinases that are involved in this 
regulation.  While HSV-1 encodes two viral kinases, US3 and UL13, ICP0 is 
extensively phosphorylated in cell culture in the absence of other viral proteins 
[50].  This observation suggests that cellular kinases are important for the 
phosphorylation and regulation of ICP0.  CK1 has been shown to phosphorylate 
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T67 in ICP0, which is important for recruiting and subsequently degrading RNF8 
[40].  Studies with the cyclin-dependent kinase (CDK) inhibitor, Roscovitine 
(Rosco), which inhibits CDK1, CDK2, CDK5, CDK7, and CDK9, have linked the 
activities of CDKs to the functions of ICP0 [39].  Specifically, Rosco impaired 
ICP0’s transactivation activity and altered the posttranslational modification 
state of ICP0 [54].  In another study, ICP0 was phosphorylated by CDK1 in vitro 
[60]; however, the biological consequence of this phosphorylation event was not 
examined.  Additionally, an interaction between ICP0 and CDK4 was identified 
via co-immunoprecipitation assays using bacterially expressed CDK4 [61], and it 
was observed that CDK6 is recruited to the nucleus of cells in the presence of a 
CDK4 inhibitor during infection [61].  Furthermore, bioinformatics programs 
identified CDK1 and/or CDK2 to be potential kinases that can phosphorylate 
residues in region 1 and 2 of ICP0 phosphorylation [39].  
Since little is known about which specific cellular kinases are necessary 
for regulating the activities of ICP0, we sought to examine this area of research.  
For this investigation, we performed a high throughput screen (HTS) using an 
established cell-based assay [62] and an siRNA library that targeted (known and 
putative) cellular kinases to determine which of these kinases may play a role in 
ICP0’s transactivation activity.  While we identified a number of cellular kinases 
from our HTS siRNA screen as potential regulators of ICP0 transactivation 
activity, we focused our efforts on CDK1, CDK2, CDK4, and, CDK6 because of 
the results from our screen and data from previously published reports that link 
these CDKs to ICP0 [54, 60, 61].  For our functional studies we used CDK 
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inhibitors of CDK1, CDK2, and CDK4/6 to study different activities of ICP0 in the 
absence of specific CDK activities.  We found that specific CDK inhibitors do 
not affect PML and sp100 dispersion mediated by ICP0.   Inhibitors of CDK1 
and CDK2 (termed CDK1i and CDK2i, respectively) impaired WT HSV-1 
replication; however, the CDK2i impaired the replication of an ICP0-null virus, 
implying that the CDK1 activity is required for ICP0-specific replication.  CDK1i 
reduces UL42 protein expression while CDK2i diminished the levels of several E 
and L proteins during WT HSV-1 infection.  CDK1i and CDK2i also reduced 
HSV-1 reactivation from a model of quiescent infection.  Based on our results, 
we conclude that CDK1 appears to regulate the expression of one HSV-1 
protein, viral replication, and reactivation from a quiescent infection in an ICP0-
dependent manner, whereas CDK2 appears to regulate viral replication in ICP0-
independent manner and reactivation in an ICP0-dependent manner.  
3.2 Materials and Methods 
 3.2.1 Cells and Viruses 
Vero cells were obtained from American Type Culture collection (ATCC) 
and cultured in Dulbecco’s Modified Eagle’s medium (DMEM) that was 
supplemented with 5% fetal bovine serum (FBS), 100 µg/mL penicillin, 100 
µg/mL streptomycin, and 2 mM glutamine as described previously [81].  HeLa 
S3 cells were generously provided by Dr. Ira J. Blader and cultured in DMEM 
supplemented with 10% FBS, 2 mM glutamine, 100 µg/mL penicillin, and 100 
µg/mL streptomycin.  HepaRG cells were generously provided by Drs. Roger 
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Everett and Chris Boutell and are a liver cell line used to study HSV and ICP0.  
HepaRG cells were cultured in William’s E medium supplemented with 10% 
FBS, 2 mM glutamine, 100 µg/mL penicillin, 100 µg/mL streptomycin, 5 µg/mL 
insulin, and 500 nM hydrocortisone.  L7 cells, a Vero cell line that stably 
expresses HSV-1 ICP0 is described in [81], were cultured in the same manner as 
Vero cells.  HFT cells are an immortalized Human Foreskin Fibroblast (HF) cell 
line and were generously provided by Chris Boutell and described and 
maintained as previously described [92].  d106 and d109 (Fig. 3.1) were used for 
in a high throughput screen and are grown as previously described [62].  d106 
expresses only ICP0 of the five IE genes, while d109 doesn’t express any IE 
genes.  Both d106 and d109 have a HCMV IE promoter-GFP cassette inserted 
into the UL54 locus.  WT KOS and 7134 (ICP0-null mutant derived from KOS 
strain) were propagated as previously described [18, 27].  Titers of KOS were 
determined via plaque assays on Vero cells, while 7134 titers were performed on 
L7 complementing cells.  in1374 was used as an indicator virus in our HSV 
reactivation studies and was generated and propagated as described in [93].  
dlx3.1, an ICP0-null mutant used as a negative control in our reactivation 
studies, was propagated as described in [94] and titered on L7 monolayers. 
 3.2.2  High throughput siRNA cell based assay 
A high throughput cell-based assay was adapted for our siRNA screen as 
described in publication [62].  Ambion siRNA against known and putative cellular 
kinases (catalog #AM80991V3) was used in the assay.  Transfected-Infected 
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plates were scanned by a Typhoon fluorescence imager (GE Healthcare) at 12, 
18, and 24 hpi to monitor GFP fluorescence.  Mitotracker fluorescent dye was 
used [250 nM] to determine relative cell density of each well at 24 hpi.  The 
relative fluorescence signal of each well was determined with the software 
program, ImageJ, as previously described[62]. 
3.2.3  CDK Inhibitors and cell cycle profile  
Specific CDK inhibitors: CDK1 inhibitor CGP74514A (CDK1i), CDK2 
inhibitor III (CDK2i), and CDK 4/6 inhibitor IV (CDK4/6i), were purchased from 
EMD Millipore Corporation.  To determine the appropriate concentration of each 
inhibitor that blocked cell cycle progression, various inhibitor concentrations 
were added to HepaRG cells (5x105) in 60 mm dishes, and cells were fixed with 
ethanol and treated with RNase.  Cellular DNA was stained using propidium 
iodide (PI), and DNA content was analyzed by Accuri C6 flow cytometer and 
Flowjo software.  The viability of the CDKi treated cells was calculated by 
staining cells with a 1:1 (vol:vol) ratio of 0.4% Trypan blue and live and dead 
cells were counted.  Percent cell viability were determined based on live number 
of cells over the total number of cells.  From these experiments, CDK1i was 
used at a concentration of 2.5 µM, CDK2i was used at a concentration of 17 µM, 
and the CDK4/6i was used at a concentration of 2 µM.  The broad CDK inhibitor, 
Rosco which inhibits CDK1, 2, likely 3, 5, 7, and 9, was used as a positive 
control at a final concentration of 75 µM.  Drugs were prepared in DMSO as 
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described per manufacturer.  Inhibitor studies were performed using a modified 
cycloheximide (CHX) block and release protocol as discussed [54]. 
 3.2.4  Immunofluorescence assays 
HepaRG cells were seeded at 5x104 cells per well on collagen-coated 
coverslips in a 24-well plate.  Twenty-four hours post seeding, cells were treated 
with CHX.  One hour post CHX-treatment, cells were infected with KOS at an 
MOI of 2.  Four hours post infection, cells were washed with phosphate buffered 
saline (PBS) and release from the CHX block.  Specific CDK inhibitors or Rosco 
was added 3.5 hpi and again after release of the CHX block.  At 2 hours post 
release (hpr), cells were fixed, permeabilized, and washed as described in 
Mostafa, et. al., 2013, except a concentration of 3.7% formaldehyde was used 
instead of 5% to fix the cells.  Cells were blocked for 1 hour at 37oC with PBS-
FB containing 1% FBS and 1% bovine serum albumin (BSA).   
 3.2.4.1  PML and ICP0 staining 
Cells were stained with primary and secondary antibodies, mounted, and 
examined as described in [43].  Cells were viewed using a Nikon fluorescent 
microscope and imaged using a CoolSNAP EZ digital camera and NSI Elements 
software.  Images were taken at the same exposure time and processed using 
Adobe Photoshop software.   
 3.2.4.2  sp100 and ICP0 staining 
Infected HepaRG cells were stained with primary and secondary 
antibodies as described in [71].  Again, cells were viewed with a Nikon 
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fluorescent microscope and imaged with a CoolSNAP EZ digital camera and NSI 
Elements software. 
 3.2.5  Viral Replication Assays 
HepaRG cells were seeded in 12-well plates at a concentration of 1x105 
cells per well.  24 h post-seeding, a CHX block and release was performed as 
described as above.  One hour after CHX was added, wells were infected with 
KOS or 7134 with a MOI of 1 PFU/cell.  Infections were synchronized by 
washing the wells with PBS three times 1 hpi, then media with CHX was added 
to the cells.  3.5 hpi, samples were pre-treated with each CDK1i, CDK2i, 
CDK4/6i, Rosco, DMSO, or mock treated while under the CHX block.  Four hpi, 
wells were washed three times with PBS and appropriate treatments were 
added.  CDK1i, CDK2i, CDK4/6i, Rosco, DMSO, and mock treatments were all 
performed.  Samples were collected and frozen at -80oC at 24 hpi.  Samples 
were sonicated and spun down prior to titering using standard crystal violet 
plaque assays on Vero (for KOS) or L7 cells (for 7134). 
 3.2.6  Western Blot Assays 
Cells were seeded in 12-well plates at a concentration of 1x105 cells per 
well.  24 hours post seeding, cells were treated with CHX and then infected with 
KOS at an MOI of 2 PFU/cell.  3.5 hpi, cells were treated with specific inhibitors 
or mock treated.  Wells were then washed with PBS 3x for 4hpi. Samples were 
processed with laemmli as previously described at 24 hpi.  Samples were ran 
out on NU-PAGE 8%-12% gradient gels at 130 volts for 90 minutes and then 
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transferred to nitrocellulose membranes.  Blots were blocked with 5% BSA 
TBST for an hour at room temperature.  Primary antibodies were used against 
ICP0 (mouse IgG2, Santa Cruz, 11060) at dilution of 1:1000, ICP4 (mouse 
monoclonal) at 1:1000, UL42 (mouse, Millipore MAB8674) 1:1000, VP5 (mouse, 
Santa Cruz, sc-56989) 1:1000, TK (mouse – a generous gift from Dr. William C. 
Summers) at 1:200, ICP8 (rabbit – a generous gift from Dr. David M. Knipe) at 
1:1000, US11 (mouse – a generous gift from Dr. Ian J. Mohr) at 1:4000, actin 
(santa cruz rabbit, sc-1616R) at 1:1000.  Antibodies were diluted in 5% BSA 
TBST and were incubated at room temperature for an hour.  Blots were then 
washed 3x with TBST.  Secondary antibodies used for the western blot were 
either goat anti-mouse horseradish peroxidase (HRP) (Jackson 
ImmunoResearch, 111-035-144) at 1:1000 or goat anti-rabbit HRP (Jackson 
ImmunoResearch, 205-035-108) at 1:1000 and were diluted with 5% BSA TBST.  
Membranes were washed 3x with TBST at room temperature.  Membranes were 
developed with either West Pico chemiluminescent substrate or West Femto 
chemiluminescent substrate.  Images of developed membranes were taken with 
a Kodak 400R image station. 
 3.2.7  Reactivation Assays 
HFT cells were seeded in 24-well plates at a concentration of 7.5x104 
cells per well.  Cells were infected with in1374 at an MOI of 0.3 PFU/cell for 24 
hours to allow for a quiescent infection to establish.  Twenty-four hpi, CHX was 
added to the wells to as previously described and either KOS or dlx3.1 was 
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used to infect wells 1 h post CHX treatment at a MOI of 1 PFU/cell.  CDK 
inhibitor treatments, and washes were done as previously described in section 
3.2.5.  Wells were then fixed at 24 hpi with 3.7% formaldehyde/PBS for 5 
minutes, then washed with PBS.  Wells were stained with X-gal [95] to detect β-
galactosidase (β-gal) activity from reactivated cells.  Cells were counted in 
various fields of view (3 per well) and blue cells were then compared to the total 
number of cells (blue/total).  These values were then compared to mock-treated, 
KOS-infected cells that were set at 100%.        
3.3 Results 
 3.3.1  A high throughput screen (HTS) identified potential cellular kinases 
that impair ICP0’s transactivation activity. 
We first set out to design a HTS to identify specific cellular kinases that 
were important for ICP0’s transactivation activity.  We used d106 and d109 
reporter viruses (Fig. 3.1) in our HTS: d106 reporter virus only expresses ICP0 of 
the five immediate early genes, while the d109 reporter virus does not express 
any IE genes.  Both viruses are replication-incompetent and express an HCMV 
major immediate early promoter driven green fluorescent protein (GFP) in place 
of the UL54 locus.  We established that ICP0 in the d106-infected cells is able to 
transactivate the HCMVMIEp-GFP compared to a control d109 that doesn’t 
express ICP0 [62].  The cell based assay was adapted to be used with an siRNA 
library against ~ 607 known and putative cellular kinases.  We were able to 
identify 21 candidates that appeared to be important for ICP0’s transactivation 
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activity based on the GFP level of the infected cells.  GFP values were 
compared to a non-cellular kinase siRNA-treated (GAPDH), d106-infected 
control, which is set at 100%.  We also established that siRNA targeting GAPDH 
was able to knockdown our target >95% by reverse transcription quantitative 
PCR and that this did not affect the GFP expression in the d106-infected wells.  
Results were considered a significant change when GFP expression was 20% or 
less of GAPDH-transfected, d106 infected cells.  The majority of the candidates 
(17) were identified at 12 hpi (Table 1), fewer candidates at 18 hpi (Table 2), and 
the least amount of candidates identified at 24 hpi (Table 3).  Candidates can be 
separated into different groups: CDKs, calcium/calmodulin-dependent kinases, 
cell morphology kinases, and signaling/metabolism kinases were identified. 
3.3.2  The protein expression of ICP0 is not notably affected by siRNA 
targeting CDK1, 2, 4, and 6.   
After identifying kinases that could potentially be important for the 
transactivation activity of ICP0, we first wanted to determine if siRNAs against 
specific cellular kinases affected ICP0 protein levels.  We reasoned that if ICP0 
protein levels were diminished in our transfected samples, there would be less 
ICP0 to transactivate HCMV mIEp-GFP in d106-infected cells, leading to false 
positive results.  For these experiments, siRNA was used to deplete the specific 
cellular kinases identified from our HTS, and wells were infected with d106 for 
12 hours.  We focused on the 12 h time point because we believe it corresponds 
with what is occurring during early lytic infection.  Western blot analysis was 
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done to determine if the depletion of a specific cellular kinase had an affect on 
ICP0 protein expression (Fig. 3.2).  CDK 1, CDC2L6, 2, 3, and others did not 
appear to affect ICP0 protein expression, and CDK4 and 6 appeared to have a 
minor affect on ICP0 protein expression (Fig. 3.2A, 3.2B) compared to a GAPDH 
transfected d106 control (G d106).  However, the depletion of CALMK1ɣ, 
CAMKIINα, CDK7, CDK8 and others did lower the expression of ICP0 (Fig. 
3.2B).   
Based on these results, we decided to focus on CDKs 1, 2, 4, and 6 
because the targeting each of these CDKs individually did not affect ICP0 
protein expression.  Also, CDKs 1 and 2 are Rosco-sensitive CDKs that were 
shown to affect ICP0’s transactivation activity [54, 55] and are potential kinases 
that phosphorylate region 1 of ICP0 [39].  ICP0 can also cause a cell cycle block 
at the G2/M checkpoint [59], which is a cell cycle transition where CDK1 and 
CDK2 are active.  Additionally, CDK4 has been shown to interact with ICP0 [61] 
and recruit cyclin D3, which interacts with CDK4 and CDK6, to ND10 bodies 
[61].  We also chose to focus on CDK4 and CDK6, as they are active during the 
G1/S transition of the cell cycle, a transition ICP0 can block [58, 59].  Notably, 
CDK4 and CDK6 have been shown to overlapping functions during the G1/S 
transition [96, 97].   
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 3.3.3  CDK inhibitors do not appreciably impair ICP0 protein expression 
using the CHX block and release method.   
We next decided to use specific CDK inhibitors to see how impairing the 
kinase activity of CDKs played a role in different functions of ICP0.  Before 
carrying out the viral replication assays, we determined optimal concentrations 
of the CDK1 inhibitor (CDK1i), CDK2 inhibitor (CDK2i), and the CDK4/6 inhibitor 
(CDK4/6i) to use by performing cell cycle analysis on PI-stained cells.  Analysis 
was done on the PI-stained, CDKi-treated cells to determine which cell cycle 
phase was blocked in and whether it corresponded with the appropriate CDK 
inhibitor.  We also determined cell viability by Trypan blue stain exclusion.  Cell 
viability was ≥95% for each (final) CDK inhibitor concentration chosen, and 
these values were comparable to mock-treated or DMSO-treated HepaRG cells 
(data not shown). 
We used the CHX block & release technique as described in [54] to 
ensure that ICP0 protein levels were not affected by impairing the CDK 
activities.  To show that the CDK inhibitors utilized in our study did not affect 
ICP0 protein levels, we used the CHX block & release technique (Fig. 3.3A) 
along with western blot assays to analyze ICP0 protein expression levels.  Fig. 
3.3B shows that neither the CDK inhibitors, the DMSO sample, nor Rosco 
appeared to appreciably impair ICP0 protein expression.  A 0 hpr sample was 
also included to show that ICP0 protein was not being expressed at the time the 
CHX block was released (Fig. 3.3B). 
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 3.3.4  CDK1 and CDK2 inhibitors impair HSV-1 replication.   
To determine which CDKs are important for HSV-1 replication, we used 
the CHX block and release assay with the CDK inhibitors and Rosco as a 
control.  When CDK1 was inhibited (CDK1i), WT HSV-1 replication was impaired 
by 200-fold (Fig. 3.4A).  WT HSV-1 was also reduced by CDK2i, but to a lesser 
extent at 50-fold (Fig 3.4A).  CDK4/6i also impaired WT HSV-1 replication, but 
only by 4-fold (Fig. 3.4A).  The control, Rosco, diminished replication by 1000-
fold (Fig 3.4A), as expected from results published in [56] and our DMSO control 
had replicated similarly to our mock-treated sample (Fig. 3.4A). 
To determine whether or not these results were ICP0 specific, we also did 
this assay with ICP0-null virus, 7134.  CDK1i reduced 7134 replication by 3-fold 
(Fig. 3.4B), which was not substantial.  CDK2i, however, impaired 7134 
replication by 195-fold (Fig 3.4B), implying the effect we saw with WT HSV-1 is 
not ICP0 specific.  Additionally, Rosco impaired 7134 replication by 245-fold 
(Fig. 3.4B). 
 3.3.5  CDK1 and CDK2 inhibitors reduce viral protein expression.  
  Next we decided to look viral protein expression to determine if it was 
affected by inhibiting specific CDKs.   We decided to use protein expression as 
an indirect readout for ICP0 transactivation activity since the transactivation 
activity of ICP0 was impaired by siRNAs against CDKs in HTS studies (Table 
3.1).  For viral protein expression, we decided to look at representative IE (ICP4), 
E (UL42, ICP8, and TK), and L (US11 and VP5) proteins.  We found that CDK1i 
42 
 
reduced UL42 levels (Fig 3.5), CDK2i impaired UL42, ICP8, US11 (Fig 3.5), and 
VP5 levels, and Rosco impaired ICP4, UL42, US11, VP5 levels (Fig 3.5), which 
was expected based on previous data that Rosco inhibits transcription of HSV-1 
genes [98].  Thus, the activities of CDK1 and 2 are associated with viral gene 
expression.   
 3.3.6  CDK inhibitors do not affect ICP0 localization, PML dispersion, or 
sp100 dispersion.    
Next we decided to examine ICP0 localization as well as ND10 dispersion 
with the CDK inhibitors to determine if the activity of specific CDKs regulated 
ND10 dispersion mediated by ICP0.  PML and sp100 staining were tested as 
they are ND10 components known to be dispersed by ICP0.  Once again, we 
used the CHX block and release technique and fixed and stained HepaRG cells 
2 hpr.  The 2 hpr time point was chosen, as ICP0 has been shown to 
disperse/degrade ND10-associated proteins >90% by this time point [99].  In 
Fig. 6A, ICP0 staining was apparent throughout the nucleus.  PML staining 
either co-localized with ICP0, was dispersed or degraded by PML, or was 
nuclear and punctate in the non-infected cells, as expected.  The staining 
pattern was the same in mock-treated versus all CDK inhibitor-treated cells (Fig. 
3.6A), and similar to results were obtained with Rosco-treated cells by Davido 
et. al., 2003 [55] .  We also obtained a similar result with sp100 (Fig. 3.6B).  ICP0 
was spread throughout the nucleus and sp100 was punctate in the non-infected 
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cells, which was disperse or degraded in infected cells that expressed ICP0 (Fig. 
3.6B).      
 3.3.7  CDK1 and CDK2 inhibitors impair ICP0-directed reactivation of viral 
gene expression from a quiescent infection.   
We infected HFT cells with in1374 to cause a quiescent infection as 
previously described [75, 93].  Specifically, in1374 contains several mutations in 
the viral genome that do not allow the virus to replicate under normal conditions: 
it contains an ICP0 deletion, a temperature sensitive ICP4, a mutated form of 
VP16 that is unable to stimulate IE gene transcription, and an HCMV IEp-lacZ in 
the TK or UL43 locus [75, 93, 100].  Previous publications have shown that 
in1374 and similar mutated viruses can infect cells and most cells will contain 
viral genomes, but they will be repressed [79, 100, 101] in a manner similar to 
latent infection.  Expression of in1374 genomes can be derepressed by 
superinfecting quiescently infected cells with HSV-1[75].  Consequently, we 
treated and infected cells as described in Fig 3.3A, after they were infected with 
in1374 for 24 hours, to determine if the CDK inhibitors have any affect on ICP0’s 
ability to activate viral gene expression from a repressed genome.   Cells were 
then fixed and stained for β-galactosidase (β-gal).  Cells that expressed β-gal 
contained reactivated virus, and random fields of view were counted for the % 
positive cells per each well (3 per well).  All samples were compared to mock-
treated, WT HSV-1 (strain KOS)-infected wells, which were assigned to be 100% 
reactivation.  CDK1i-treated cells only had 14.7% reactivated viral gene 
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expression compared to mock-treated cells (Fig 3.7).  CDK2i-treated cells had 
3.4% reactivated viral gene expression compared mock-treated cells (Fig 3.7).  
CDK4/6i treated cells reactivated viral gene expression to levels near mock-
treated cells, while Rosco-treated cells reactivated as nearly the same as dlx3.1  
(ICP0-null mutant) superinfected levels (Fig 3.7), demonstrating that ICP0 was 
required to activate viral gene expression from a repressed genome. 
3.4 Discussion 
With our high throughput cell based assay or HTS, we were able to 
identify a number of specific cellular kinases that were potential regulators of 
ICP0’s transactivation activity (Tables 3.1-3.3).  As part of our initial efforts to 
limit specific kinases of interest, we decided to exclude siRNA kinase targets 
that decreased ICP0 protein levels from our HTS (Fig. 3.2).  With the remaining 
kinases in our siRNA screen, we decided to examine the role of CDKs 1, 2, 4, 
and 6 in ICP0’s transactivation activity, as our data in this chapter and results 
from previously published reports indicated a potential association between 
these kinases and ICP0 [39, 54, 60, 61].  As we wanted to determine the role 
these kinases played in ICP0’s functions and lytic infection and reactivation, we 
used commercially available CDK inhibitors that specific blocked the kinase 
activities of CDK1, CDK2, or CDK4/6.  With these inhibitors, ICP0’s stimulation 
of viral gene expression and ND10 disruption (Figs. 3.5 and 3.6), HSV-1 
replication (Fig. 3.4), and ICP0-mediated stimulation of viral gene expression 
from a quiescent infection (Fig. 3.7) were examined.  Our data showed that 
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CDK1i reduced UL42 protein levels (Fig. 3.5), while CDK2i decreased the 
expression of multiple viral proteins: UL42, ICP8, US11, and VP5 (Fig. 3.5).  
Rosco also impaired viral protein expression similarly to CDK2i.  
Immunofluorescence assay demonstrated that ICP0 localization and the 
dissociation of ND10 components were not affected regardless of which CDK 
inhibitor was tested (Fig. 3.6).  Viral yield assays showed that WT HSV-1 
replication was inhibited 200-fold by CDK1i (Fig. 3.4A), whereas CDK2i caused a 
50-fold decrease (Fig. 3.4A).  Rosco diminished WT replication by 1000-fold 
(Fig. 3.4A), while CDK4/6i only impaired HSV-1 replication by 4-fold.  When 
replication of the ICP0-null mutant was examined, its yields were only impaired 
by CDK2i (195-fold) and Rosco (245-fold) (Fig. 3.4B).  Finally, reactivation of viral 
gene expression from quiescently infected cells was reduced to 14.7% with 
CDK1i compared to the mock-treated control (100%) (Fig. 3.7).  CDK2i also 
inhibited the induction of viral gene expression to 3.4%, and inhibition by Rosco 
approached 0%, which was similar to superinfection with the ICP0 null mutant, 
dlx3.1 (Fig. 3.7).   
The majority of our results were obtained using inhibitors that selectively 
impair one or more CDKs from phosphorylating their target(s).  CGP74514A (i.e., 
CDK1i) has been reported to be a specific CDK1 inhibitor with an IC50 of 25 nM 
in vitro.  Although CDK1i can inhibit other kinases, it requires a significantly 
higher concentration (i.e., IC50 = 6.1 µM for PKCα, 125 µM for PKA, and >10 µM 
for EGFR) [102], and several publications have shown that CDK1i specifically 
inhibits the activity of CDK1 [102-104].  A report by Wei, et. al., 2011, indicated 
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that CDK1 was specifically inhibited at 2 µM in cell culture, which is the same 
concentration used in our studies.   Also, we used the CDK2 Inhibitor III (i.e., 
CDK2i), also known as CVT-313, in our experiments with ICP0 and HSV-1.  
Despite its potential to inhibit other CDKs at different IC50s in vitro (e.g., 0.5 µM 
for CDK2/cyclin A and 0.5 µM CDK2/cyclin E; 4.2 µM for CDK1/cyclin B; 215 µM 
for CDK4/cyclin D1) [105], previous publications indicate that CDK2i impaired 
CDK2 in cell culture at 25 µM [106]; we used a similar concentration in our tests.  
While it is plausible that CDK2i could block CDK1/cyclin B activity, results from 
Bhattacharjee, et al., 2001 suggest that this possibility is unlikely.  In either case, 
CDK2i has a higher affinity for inhibiting CDK2 kinase activity [107].  Lastly, we 
treated cells with the CDK4/6 Inhibitor IV (i.e., CDK4/6i) or CINK4 at 2 µM, and it 
was reported that CDK4/6i has an IC50 of 1.5 µM for CDK4 and 5.6 µM for 
CDK6.  Little to no inhibition has been reported for CDK4/6i against CDK1/cyclin 
B, CDK2/cyclin A, or CDK2/cyclin E (IC50 >10 µM) [108].  Of note, when we 
tested CDK4/6i at concentrations >2 µM in cell culture, cell death was plainly 
visible, which is why 2 µM was chosen for our experiments. 
Our data with specific CDK inhibitors indicate that WT viral growth 
requires the activities of CDK1 and CDK2 for efficient replication in cell culture, 
where CDK2 activity is necessary for high levels of ICP0-null mutant replication.  
Rosco, which inhibits multiple CDKs, also diminished HSV-1 replication in our 
experiments, analogous to one published study [56].  Thus, our data strongly 
suggests that CDK1 enhances HSV-1 lytic replication in an ICP0-dependent 
manner, and CDK2 stimulates acute replication in a manner that is not (at least 
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partially) dependent on ICP0.  We propose that CDK1 interacts with and 
phosphorylates ICP0 to regulate one or more or its activities (but not ND10 
disruption) to stimulate HSV gene expression and enhance lytic replication.  In 
support of this possibility, bioinformatics studies have shown that CDK1 is one 
of several potential kinases to phosphorylate ICP0 [39] and one published report 
showed that CDK1 can phosphorylate the N-terminal third of ICP0 in vitro [60], 
which contains Phospho-region I.  Phosphorylation of ICP0 in regions I and II 
was also found to be required for efficient HSV-1 replication in cell culture 
and/or acute infection in mice [41-43], linking kinases to ICP0 functions and viral 
growth.  Although it is plausible that CDK2 has the potential to phosphorylate 
ICP0 and modulate one or more of its activities, our data suggest that CDK2 is 
an important regulator of other steps or aspects of the HSV-1 replication cycle.  
As inhibiting CDK2 greatly diminished E and L protein levels, it is likely that 
CDK2 is important for regulating the activities of two or more IE proteins.  
Notably, Rosco, which inhibits both CDK1 and CDK2, impairs viral transcript 
accumulation and DNA replication [98, 109, 110].  However, given the parallels 
between Rosco and CDK2i in our experiments implies that inhibition of CDK2 is 
a significant contributor to Rosco’s phenotypes with HSV-1 during lytic infection 
in cell culture. 
Rosco has also been shown to inhibit explant-induced reactivation from 
neurons [57], demonstrating that CDK activities are important for ex vivo 
reactivation.  In our study, we showed that CDK1 and CDK2 are important for 
reactivation of viral gene expression from quiescently infected cells.  In this 
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regard, the aforementioned study demonstrated that latently infected neurons 
from mice that underwent explant-induced reactivation induced the expression 
of CDK2 and CDK4 [57] and not CDK1, which potentially contrasts with the 
results of our reactivation experiment.  CDK1 could still play an important role in 
explant-induced reactivation for HSV-1.  Specifically, CDK1 expression could be 
at or below the limit of detection in neurons by immunohistochemistry in the 
aforementioned study and its kinase activity (along with other CDKs) was not 
examined [57].  Also, unlike the Schang study where explant-induced 
reactivating neurons expressed CDK4, CDK4/6i did not impair reactivation from 
quiescent infection in HFT cells.  Although CDK4 was not expressed in resting 
neurons, it was expressed in explant-induced reactivated neurons [57].  One 
plausible set of explanations about the differential results from our studies with 
ex vivo mouse ganglia model are the cell types (neurons vs. fibroblasts) and 
species (mouse vs. human) used in the model systems.  Additionally, it is 
possible that CDK2 directs reactivation in neurons, since bioinformatics 
suggests it is a potential phosphorylator of phos-region 1 and 2 of ICP0 [39], 
and Schang, et. al., 2002 [57] showed explant induced reacted neurons 
expressed CDK2, implying that this CDK may be important for HSV-1 
reactivation.  In future studies, we would like to determine if the activity of the 
CDKs in question are important for HSV-1 reactivation in a mouse ex vivo model 
system. 
Studies with other quiescent infection-reactivation systems have shown 
that ICP0, specifically its RING finger, is important for reactivation from 
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quiescently-infected cells [111].  The RING-finger motif of ICP0 also facilitates 
the removal of histones and repressive chromatin marks on quiescent viral 
genomes [111], aiding in reactivation as latent viral DNA is known to be 
chromatinized [112], bound by nucleosomes [112, 113], and display very low or 
limited lytic gene expression [114, 115].  Though it is not known whether specific 
CDKs are important for regulating these functions of ICP0 during reactivation, 
our activation of viral gene expression from a repressed genome suggest a 
potential role for CDKs 1 and 2 activities through ICP0 in reactivation to modify 
the viral chromatin state (Fig. 3.7), which is an area of future investigation. 
Our study also provides another example of how CDKs appear to be 
important in life cycles of other herpesviruses.  In this context, Rosco inhibited 
the replication of varicella-zoster virus (VZV), an alphaherpesvirus related to 
HSV-1 and -2, both in cell culture and in mice [116, 117].  Upon VZV infection, 
the protein expression of CDK1 and CDK2 is increased as well as the kinase 
activities of CDK2 and CDK4 [118].  VZV also induced the activity of CDK2 and 
CDK4 in non-dividing cells, implying that these CDKs may be important for VZV 
replication [119].  CDK1 does play a direct role in the VZV life cycle by 
phosphorylating a VZV major IE protein transactivator, IE62 [120], and CDK1 is 
incorporated into VZV virions [120]. Rosco and cells expressing a dominant-
negative CDK2 were shown to inhibit transcription and replication of the beta-
herpesvirus, human cytomegalovirus (HCMV) [121, 122]. Lastly, the 
gammaherpesvirus, Epstein-Barr virus (EBV), requires the activities of Rosco-
sensitive CDKs to reactivate from B cells [123].  Our data extend the 
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understanding and highlight the importance of CDKs in virus-host interactions, 
facilitating the switch between lytic and quiescent infections of herpesviruses. 
3.5 Tables  
Function/family HTS Cellular Kinase Candidates 
Cell cycle/cyclin-dependent 
kinases (CDK) 
CDK1, CDK2, CDK3, CDK4, CDK5, 
CDK6, CDK7, CDK8, CDK11, CDK13 
Calcium/calmodulin-dependent 
kinase (CALM/CAMK) 
CALM3, CAMK1G, CAMK2B, 
CAMK2D, CAMK2A 
Cell Morphology CDC42BPA, CDC42BPB, CDC42BPG 
Signaling/Metabolism DOK1 
CALM= Calmodulin, CAMK= calcium/calmodulin dependent protein 
kinase, CDC42 = CDC42 binding protein kinase, DOK1 – docking protein 1 
62kDA 
Table 1 Cellular kinases at 12 hpi ≤20% compared to siRNA against 










Function/family HTS Cellular Kinase Candidates 
Cell cycle/cyclin-dependent 
kinases (CDK) 
CDK1, CDK2, CDK3, CDK6, CDK11 
Cell Morphology CDC42BPA 
Signaling/Metabolism DOK1 
CDC42 = CDC42 binding protein kinase, DOK1 – docking protein 1 
62kDA 
Table 2 Cellular kinases at 18 hpi ≤20% compared to siRNA against 
GAPDH d106 control set at 100%.  The screen was repeated 3 times. 
 





DOK1 – docking protein 1 62kDA 
Table 3 Cellular kinases at 24 hpi ≤20% compared to siRNA against 







3.6 Figures and Figure legends 
 
Figure 3.1 HSV-1 recombinant viruses, d106 and d109, utilized in our siRNA 
screen against known and putative cellular kinases. 
Schematic of viruses used in the high throughput cell based assay.  This 





Figure 3.2  Affect of specific kinase siRNAs against on ICP0 protein levels 
in d106-infected cells.   
Cells were transfected with siRNAs against specific cellular kinases in a 
96-well plate and infected with d106.  An siRNA against GAPDH  (G d106) was 
used as a control.  Samples were collected at 12 hpi and separated on SDS-
PAGE, and membranes were probed for ICP0 and actin.  A representative set of 




Figure 3.3  CDK inhibitors do not noticeably decrease ICP0 protein levels 
when added after release from a CHX block. 
A) Schematic of a CHX block and release that is extensively used in 
subsequent experiments.  CHX was added at concentration of 50 µg/mL 24 h-
post seeding and 1 h prior to infection.  Wells were treated with specific 
inhibitors 3.5 hpi.  At 4 hpi cells were either harvested or released into medium 
with or without various treatments and samples were collected 24 hpi unless 
specified otherwise.  B)  HepaRG cells were infected with WT HSV-1 (KOS) at an 
MOI of 2 PFU/cell using the CHX block and release into the following inhibitors 
or treatment groups.  Samples were analyzed for ICP0 and actin protein levels.  
M, Mock; D, DMSO; 1i, CDK1i; 2i, CDK2i; 4/6i, CDK4/6i; R, Rosco; 0hpr, 0 h 
post release.  A representative set of images is shown, from 3 independent 





Figure 3.4  CDK inhibitors impair HSV-1 replication. 
HepaRG cells were infected with KOS (WT HSV-1) (A) or 7134 (ICP0-null 
mutant) (B) at an MOI of 1 PFU/cell using a CHX block and release as described 
in Fig. 3.3A.  Specific inhibitors were added 30 minutes prior to CHX release and 
after the CHX release.  Samples were collected 24 hpi, frozen at -80°C, 
sonicated, and then titered out on appropriate cell line. Samples were done in 




Figure 3.5  CDK inhibitors reduce the expression of a subset of HSV-1 
proteins.    
HepaRG cells were infected using the CHX block and release method 
with KOS (WT HSV-1) at an MOI of 2 PFU/cell as described in Fig. 3.3A.  
Samples were harvested at 24 hpi.  Viral protein and actin levels were 
determined by western blot analyses.  M, Mock; D, DMSO; 1i, CDK1i; 2i, CDK2i; 
4/6i, CDK4/6i; R, Rosco; 0 hpr, 0 hours post release. A representative set of 




Figure 3.6  CDK inhibitors do not appear to alter ICP0 localization or 
disruption of ND10s. 
HepaRG cells were infected with KOS (WT HSV-1) at a MOI of 2 PFU/cell 
using the CHX block & release in Fig 3.3A, except cells were fixed and 
permeabilized at 2 hpr.  Immunofluorescence staining was performed to detect 
ICP0 and PML or ICP0 and sp100 expression.  A) ICP0 (green) and PML (red) 
staining are in the Merge images.  B) ICP0 (red) and sp100 (green) staining are in 
the Merge images.  A representative set of images is shown from three 




Figure 3.7  Specific CDK inhibitors diminish ICP0-directed reactivation of 
viral gene expression from quiescent infection.   
HFT cells were quiescently infected with in1374 at a MOI of 0.3 PFU/cell.  
Twenty-four hpi, cells were infected with KOS (WT HSV-1) or dlx3.1 (ICP0-null 
mutant) at an MOI of 1 PFU/cell using the CHX block & release in Figure 3.3A.  
After 24 hpi superinfection, wells were fixed and stained for β-gal activity.  β-gal 
positive and negative cells were counted to determine the relative % of β-gal-
positive cells. The value for KOS-infected, mock-treated samples (Mock) was 
set as 100% for efficiency of reactivation (viral gene expression).  All treatments 







Chapter 4: Conclusions & Future Directions 
In order to begin to determine what cellular kinases are important for 
regulating functions of ICP0, we developed a high throughput cell-based assay 
(Chapter 2) that we used with an siRNA library against known and putative 
cellular kinases (Chapter 3).  We identified a number of specific targets of which 
we decided to narrow down our list of potential candidates by determining 
which siRNA candidates siRNA did not noticeably alter ICP0 protein expression 
and then decided to focus our studies on CDK1, CDK2, CDK4 and CDK6.  We 
used specific CDK inhibitors to determine that inhibiting CDK1 impairs WT HSV-
1 replication while it does not impair ICP0-null mutant replication.  The CDK2 
inhibitor impairs both the replication of WT HSV-1 and an ICP0-null virus.  
Rosco also greatly reduced viral replication, while CDK4/6i did not impair HSV-1 
replication.  To begin to elucidate potential mechanisms of how HSV-1 
replication was impaired, we next examined the expression of a subset of HSV-
1 proteins. Viral protein expression was used as a readout of ICP0 
transactivation activity.  CDK1i decreased UL42 levels, while CDK2i, and Rosco 
had a much greater affect, diminishing UL42, ICP8, US11, and VP5 levels.  
CDK4/6i did not alter the expression of the viral proteins we examined.  We next 
decided to see if the activities of specific CDKs were required for ND10 (PML 
and sp100) dispersion by ICP0 or if CDK inhibitors had an affect on ICP0 
localization.  None of the CDK inhibitors or the Rosco control affected ICP0 
localization or it ability to disperse ND10 components.  Finally, we examined 
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ICP0’s ability to reactivate viral gene expression from a quiescent HSV-1 
infection in the presence of specific CDK inhibitors.  We found that CDK1i, 
CDK2i, and Rosco all reduced the viral gene expression from quiescent HSV-1 
infection compared to WT HSV-1 viral gene expression or de-repression of the 
viral genes. 
Based on our results in Chapter 3, we propose that CDK1 interacts with 
and phosphorylates ICP0 and this event is required for the transactivation 
activity of ICP0, which is based on our results from the siRNA screen and 
reduced UL42 levels, which then aids HSV-1 to achieve maximum levels of lytic 
infection and efficient viral gene activation from quiescent infection (Fig. 4.1). 
Several lines of evidence support this hypothesis. CDK1 can directly 
phosphorylate an N-terminal portion of ICP0 (residues 20-241) in vitro [60].  This 
portion of ICP0 contains region I (residues 224-232) of ICP0 phosphorylation 
that was first identified in infected cells; region I also contains potential 
phosphorylation sites for CDK1 or CDK2 [39].  Furthermore, the viral mutant 
Phos 1, which block phosphorylation sites in region I, is impaired for ICP0 
transactivation activity and for viral replication in cell culture (similar to our 
CDK1i studies) and in a mouse model lytic replication and reactivation [39, 41-
43].  Fine mapping studies of this region went on to show that serine 224 of 
Region I plays a major role in ICP0 activities and viral growth [43]. 
In future studies, we plan to determine whether ICP0 phosphorylation is 
directed by CDK1.  We plan to employ our CHX block and release protocol 
infecting cell cultures with WT HSV-1 and use inducible RNAi vectors to either 
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deplete CDK1 or inhibit CDK1 (with CDK1i as in Chapter 3) to inactivate CDK1 
during viral replication.  ICP0’s phosphorylation profile would be examined by 
tandem mass spectrometry in either depleted vs. control (for RNAi) or inhibitor-
treated vs. vehicle-treated samples.  To determine whether ICP0 interacts with 
CDK1 in cells, we propose performing co-immunoprecipitation in cell culture or 
(mammalian or yeast) two-hybrid assays.  Should CDK1’s interaction with ICP0 
be transient in nature, we would use a dominant-negative version of CDK1 to 
stabilize this interaction.  It is also possible, though less likely, that CDK1 
indirectly regulates activities of ICP0.   
Many publications have linked HSV to the cell cycle and CDKs.  One 
report with the broad CDK inhibitor, Rosco, showed that it attenuates lytic 
replication [56], which initially suggested that the activities of CDKs are 
important for HSV-1 replication.  Subsequent studies demonstrated that Rosco 
inhibited ICP0 transactivation of the HSV-1 ICP6 promoter, blocked viral DNA 
synthesis, and significantly reduced immediate-early and early transcript levels 
[54, 56, 98, 109].  Our studies with CDK2i appear to mirror many of the 
phenotypes observed with Rosco, strongly suggesting that the CDK2 inhibition 
is largely responsible for the HSV-1 phenotypes with Rosco.  Overall, these data 
indicate that CDK activities modulate, in part through ICP0, many steps in the 
HSV life cycle,  
While CDKs appear to regulate HSV-1, WT HSV-1 can also block the cell 
cycle in proliferating cells at G1/S boundary [124] or alter CDK activity [124].  
Notably, HSV-1 infection can also block certain events in the G1 phase of the 
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cell cycle, including limiting increases in cyclins D1 and D3 levels, which are 
important for the G1/S transition [125].  Furthermore, infecting cells in the G1 
phase with HSV-1 prevents cell cycle progression into the S phase [126].  When 
quiescent cells are infected with HSV-1, there is a loss of CDK4/6/cyclin D 
activity and an inhibition of CDK2/cyclin E activity [124].  WT HSV-1 replication 
in asynchronously dividing cells decreases CDK2/cyclin E and CDK2/cyclin A 
activity [124].  Though CDK2/cyclin E and CDK2/cyclin A activity decrease, 
these decreases occur later in the HSV-1 lytic infectious cycle, suggesting this 
decrease is an effect of viral infection.  Another publication demonstrated that 
CDK2/cyclin A activity and expression increase early during lytic infection, but 
eventually decrease over time compared to serum-stimulated cells [127].  This 
latter study and our experiments showing CDK2i impairs HSV-1 replication, 
gene expression, and viral gene activation from quiescent infection implicate a 
pivotal role for CDK2 in the HSV-1 reproductive cycle.  There is also evidence 
from the Roizman group that ICP0 interacts with cyclin D3 to activate CDK4 
kinase activity, though it was activated to a lesser degree than in mock-infected 
samples [128-130].  Notably, an ICP0 cyclin D3 binding mutant has no 
discernable replication phenotypes in cell culture, which correlates with our 
CDK4/6i data, although this ICP0 mutant was less neuroinvasive in mice [129]. 
Thus, the activities of CDK4 and/or CDK6 during HSV-1 infection may only be 
apparent in vivo, in neurons, or both.  Lastly, using a variety of HSV-1 mutants, 
ICP0 was shown to mediate cell cycle blocks at G1/S and G2/M [58, 59], 
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suggesting that the activation or inhibition of cellular factors or functions by 
ICP0 during these transition states may be important for HSV-1 replication. 
In looking at downstream effects of CDKs on ICP0 functions, examination 
of its E3 ubiquitin ligase activity upon CDK inhibition is one major area of 
interest.  ICP0 is known to degrade components of ND10s as a subset of its 
cellular targets.  Data from our immunofluorescence experiments in Chapter 3 
indicate that the activities of CDK1, CDK2, and CDK4/6 are not required for PML 
and sp100 dispersion, which corresponds with a previously published report 
[55] using the CDK inhibitor, Rosco. Outside of ND10-associated proteins, it is 
possible that ICP0 either mediates the ubiquitination and subsequent 
degradation or dispersal of other ICP0 target proteins.  Relating kinase function 
to phosphorylation, genetic studies using ICP0 phosphorylation mutants have 
shown that ICP0 phosphorylation regulates its E3 ubiquitin ligase activity 
through protein stability by autoubiquitination and via another known target 
protein, USP7 [43].  In the absence of other viral factors, at least one ICP0 
phosphorylation mutant form does not result in the formation polyubiquitin 
chains in cell culture [41]. 
To determine if CDKs influence ICP0’s E3 ubiquitin ligase activity, we 
propose carrying out several experiments.  The most straightforward approach 
would be to examine if CDK1 inhibitors impair the ability of ICP0 to form 
polyubiquitin chains in vitro or cell culture [41] or affect ICP0 stability during 
infection using the CHX block and release protocol.  If these steps in ICP0 
ubiquitination would not be affected by CDK inhibition, proteomic approaches 
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(the host proteome or ubiquitinome) could be performed to identify potential 
cellular targets whose ubiquitin status are decreased and/or stability are 
increased in the presence of ICP0 by blocking CDK1 activity.  The identity of 
such targets would suggest that ICP0 differentially directs the degradation or 
ubiquitination of these proteins in a CDK1-dependent manner, likely impacting 
viral gene expression and lytic infection. 
In addition to determining whether CDK1 affects ICP0’s E3 ubiquitin 
ligase activity in cell culture, we would also like to know whether CDK1 affects 
ICP0 functions and HSV-1 pathogenesis in vivo.  For these future experiments, 
we would use the mouse ocular model of HSV-1 infection.  Specifically, we 
propose testing the replication of WT HSV-1, an ICP0 null mutant, and ICP0 
phosphorylation mutants (e.g., Phos 1) in a WT and CDK1-knockout mouse.  
Such a system would allow us to examine acute infection in the eyes and 
neurons of the trigeminal ganglia, latency, and reactivation after explantation.  
We would predict that CDK1 is required for ICP0-dependent acute (peripheral 
and neuronal) replication in lytic infection and reactivation from latency, 
reflecting the results we see in Chapter 3, and a previous published study that 
Rosco inhibits reactivation in explant induced reactivation [57] and that ICP0 
phosphorylation mutants are diminished in their ability to replicate lytically and 
reactivate from latency [42].   
 Since it appears that CDK2 enhances HSV-1 lytic replication in what 
appears to be an ICP0-independent manner and contributes to robust viral 
protein expression, we also want to begin to elucidate how CDK2 contribute to 
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HSV-1 productive infection.  For these studies, we would inhibit CDK2 using our 
CHX block and release technique and infect cells with HSV-1 and perform RNA-
seq to determine which viral transcripts are being expressed or impaired.  Our 
data from Chapter 3 suggest that transcription may be impaired for at least 
several viral transcripts, as viral protein expression is attenuated similarly to 
what is seen in Rosco-treated samples.  If transcription is impaired, we could 
also test whether or not viral DNA replication is blocked by performing real time 
PCR to quantitate viral genome numbers.  Given the similar effects of CDK2i 
and Rosco in our assays and the inhibitory effects of Rosco on the HSV-1 lytic 
phase of infection [54, 56, 57, 109], we would predict that CDK2 participates in 
IE transcription, E transcription, and viral DNA replication. 
 It is possible that while one CDK is important for the lytic replication cycle 
in an ICP0-dependent manner, our data suggest that CDK1 and CDK2 may be 
important for reactivation.  Specifically, inhibition of CDK1 or CDK2 restricts 
ICP0 activation of viral gene expression from a cell culture model of quiescent 
infection.  This model system has been used to study HSV-1 latency and 
reactivation, given the similarities between cell-based and neuronal cultures.  
Specifically, the HSV-1 genome doesn’t integrate into the host genome during 
latency, but is instead chromatinized as an episome in latently infected the 
neurons of mice [112] and the genomes of quiescently infected non-neuronal 
(human fibroblast) cells also become chromatinized [37, 113].  During neuronal 
latency there is limited or no lytic gene expression [131, 132], which is 
analogous to what happens in cell-based quiescent infections [37, 78].  These 
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reactivation cell culture model systems have also begun to elucidate certain 
factors that modulate quiescent infection and de-repression of that HSV-1 
genome and how ICP0 influences these processes [37, 75, 111].  Notably, the 
expression of ICP0 in these models promotes the switch from repressive 
heterochromatin markers to transcriptional active euchromatin markers on the 
HSV-1 genome, which is followed by an increase in transcription. 
Though there is limited information about what role CDKs and cyclins 
play in latency and reactivation, Schang, et. al., 2002 showed that mock-
infected mouse sensory neurons did not express any CDK1 or CDK2, while 
explant-induced reactivated neurons expressed CDK2 and CDK4 with 
interacting partners cyclins E and D, respectively, further supporting a role for 
CDK2 and ICP0 in HSV reactivation.  There are several studies that have shown 
that CDKs are expressed in neurons when subjected to stress or death-inducing 
stimuli [133-139], although most CDKs that are important for cell cycle 
progression are not typically expressed in differentiated, post-mitotic neurons.  
CDKs 1, 2, 4, and 6 have also been shown to be induced and expressed during 
neuronal apoptosis [133, 136, 138, 140-142], a stress that can be associated 
with HSV reactivation.  Based on the collective parallels between non-neuronal 
and neuronal models of quiescent infection and our own quiescent data, it is 
conceivable that CDK1 and/or CDK2 stimulate HSV reactivation in neurons by 




4.2 Figures and Figure legends 
 
   
Figure 4.1 Model for how CDK1 activity regulates functions of ICP0, HSV-1 
replication, and reactivation. 
We propose that 1) CDK1 phosphorylates ICP0, which is 2) required for it’s E3 
ubiquitin ligase activity.  ICP0’s E3 ubiquitin ligase activity and 3a) CDK2 is 
important ICP0 transactivation activity.  The E3 ubiquitin ligase activity and 
phosphorylation of ICP0 is also important for dispersion of PML bodies in the 
absence of viral proteins [41].  3b) The dispersion of PML bodies also aids the 
transactivating activity of ICP0.  4a) These activities contribute to efficient HSV-1 
lytic infection and 4b) efficient activation of quiescent genomes from quiescently 
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HSV-1 infected cells in cell culture while 5a and 5b indicate potential 
relationships between CDK1 and ICP0 in vivo or in a mouse model.  5a) 
indicates lytic replication while 5b) indicates reactivation in vivo 6) We also 
propose that CDK2 potentially phosphorylates ICP0 and 7) CDK2 activity is 
needed for efficient activation from quiescent genomes.  Black arrows indicate 
known steps in ICP0, while grey arrows with “?” indicate hypothetical steps or 
relationships.  The grey arrow without the question mark is a known link or step 
that does not require CDK1 or CDK2.  The dashed arrow indicates the 
relationship is based on the data from the siRNA screen and decreased UL42 
levels when CDK1 activity was inhibited. 
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